• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Pouchitis - Pipeline Review, Q4 2010

  • ID: 1464267
  • December 2010
  • 20 pages
  • Global Markets Direct

Pouchitis - Pipeline Review, Q4 2010


Global Markets Direct’s, “Pouchitis Pipeline Review, Q4 2010”, provides an overview of the Pouchitis therapeutic pipeline. This report provides information on the therapeutic development for Pouchitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pouchitis. “Pouchitis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.


- A snapshot of the global therapeutic scenario for Pouchitis.
- A review of the Pouchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.

Note: Product cover images may vary from those shown

List of Tables
List of Figures
Global Markets Direct Report Coverage
Pouchitis Overview
Therapeutics Development
An Overview of Pipeline Products for Pouchitis
Pouchitis Therapeutics under Development by Companies
Companies Involved in Pouchitis Therapeutics Development
Ocera Therapeutics, Inc.
Atlantic Pharmaceuticals, Inc.
AesRx, LLC.
Pouchitis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Secondary Research
Primary Research
Expert Panel Validation
Contact Us

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Pfizer, Inc. Grünenthal GmbH GlaxoSmithKline PLC Abbott Laboratories Ltd. Roche Diagnostics Ltd. Novo Nordisk A/S